Ontology highlight
ABSTRACT:
SUBMITTER: Sasaki T
PROVIDER: S-EPMC3477548 | biostudies-literature | 2011 Dec
REPOSITORIES: biostudies-literature
Sasaki Takaaki T Jänne Pasi A PA
Clinical cancer research : an official journal of the American Association for Cancer Research 20111018 23
The identification of oncogenic alterations in subsets of patients with non-small cell lung cancer (NSCLC) is transforming clinical care. Genomic rearrangements in anaplastic lymphoma kinase (ALK) are detected in 3% to 7% of patients with NSCLC. The ALK tyrosine kinase inhibitor crizotinib has demonstrated clinical efficacy in ALK-rearranged NSCLC patients and was recently approved by the U.S. Food and Drug Administration. Crizotinib is currently under additional phase III clinical development a ...[more]